Alvopem ® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
ConclusionsThe results of this open-label, observational PMS showed that Pemetrexed (Alvopem®) is safe in patients with non-squamous NSCLC patients receiving pemetrexed-containing regimens.Trial registration: The trial was registered at ClinicalTrials.gov (NCT04843007) in April 13th, 2021.
Source: Journal of Pharmaceutical Policy and Practice - Category: Pharmaceuticals Source Type: research
More News: Alimta | Anemia | Asbestosis | Cancer | Cancer & Oncology | Iran Health | Lung Cancer | Mesothelioma | Middle East Health | Nanotechnology | Non-Small Cell Lung Cancer | Pharmaceuticals | Statistics | Study | Women